Современные подходы в диагностике и лечении медуллярного рака щитовидной железы

Казубская Татьяна Павловна, Козлова Валентина Михайловна, Faina A. Amosenko et al. · Вестник РОНЦ им. Н. Н. Блохина РАМН · 2011

Genetic analysis of hereditary mutations of gene RET shows a way to effective diagnosis and prevention of medullary thyroid cancer. DNA diagnosis targets at point mutations in RET exons 10, 11, 13, 14, 15, 16. Examination of 68 families of medullary thyroid cancer patients and 382 their blood relatives discovered genetic medullary thyroid cancer in 24.9% of cases including multiple endocrine neoplasia syndrome types 2A (7.4%) and B (11.7%), familial medullary thyroid cancer syndrome (4.4%) and medullary thyroid cancer as a component of neurofibromatosis type 1 (1.4%). In patients with multiple endocrine neoplasia syndrome type 2A RET mutation in codon 634 was found to be associated with pheochromocytoma and hyperparathyroiditis, and mutation in codon 918 was characteristic of multiple endocrine neoplasia syndrome type 2B and associated with mucosal neurinomas and skeleton malformations. This discovery helps to make a more accurate prognosis of disease course in patients with multiple endocrine neoplasia syndrome type 2. Direct RET testing in relatives of patients with multiple endocrine neoplasia syndrome type 2A identified 8 carriers of germinal mutations of this gene. Prophylactic surgery was made in 6 of them. This surgery appeared preventive in 2 (3.5 and 9 years old) cases, and was performed at an early disease stage in 4 (aged 14 years or older). Mean postoperative disease-free follow-up was 7 years. Germinal de novo RET mutation was found in 1 of 13 patients with sporadic medullary thyroid cancer. This proves reasonable DNA testing in cases with sporadic medullary thyroid cancer. A comprehensive program was developed to identify individuals predisposed to medullary thyroid cancer.

Cited by 0 works.

Authors